Mutations in the LRRK2 gene, which have been associated with a high risk of Parkinson’s disease, may affect neurons by promoting cell death through the activation of a protein called PIG3, according to results of a study presented at the recent Society for Neuroscience 2016 meeting in San Diego. The study’s…
News
Several factors contribute to the outcome of patients with Parkinson’s disease who undergo deep brain stimulation (DBS), according to a new study. The research paper, “Short-term Adverse Outcomes Following Deep Brain Stimulation Treatment in Parkinson’s Disease Patients,” was published in the journal World Neurosurgery. DBS is a…
Prothena‘s potentially disease-modifying treatment for Parkinson’s disease, PRX002, met the primary objective in a Phase 1b multiple ascending dose clinical trial. The drug was found to be safe and well tolerated. PRX002 was also found to deeply penetrate the central nervous system in all doses tested. Levels of free…
A new method to encapsulate single cells in alginate hydrogels, a material derived from a sugar naturally-occurring in brown seaweed, could improve the delivery of therapeutic substances to the body and be used for the treatment of many diseases including Parkinson’s disease, according to a study published in the leading scientific journal Nature Materials.
International Stem Cell Corporation discussed advance work, leading to the first clinical trial to explore parthenogenetic stem cell transplants for patients with Parkinson’s disease, at the ongoing Society for Neuroscience 2016 Annual Meeting in San Diego. The presentation, “Transplantation of neural stem cells for parkinson’s disease, an update of the first-in-human clinical…
Researchers at Mayo Clinic’s campus in Florida have found a genetic mutation that may increase the risk for developing Parkinson’s disease earlier than usual. The study, “Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism,” was published in the journal Brain. The result of a…
Intec Pharma recently announced that the protocol for the global Phase 3 Accordance clinical trial (NCT02605434) has been amended. The Accordance trial, which is currently recruiting patients, is evaluating the Accordion Pill Carbidopa/Levodopa to treat symptoms of Parkinson’s disease in patients with advanced stage disease. Following suggestions…
Low selenium intake may increase the risk of developing Parkinson’s disease in people carrying a particular genetic mutation, according to a study on environmental and genetic interactions and their impact on Parkinson’s disease (PD) development. The research demonstrated that cataloging knowledge of gene-environment interactions is indispensable for leveraging knowledge from…
Brain inflammation suffered by athletes in contact sports like football appears to be directly linked to chronic traumatic encephalopathy, a cause of dementia, and may lead to neurological diseases like Parkinson’s, according to a study in the journal Acta Neuropathologica Communications. Indeed, the authors argue that American football players and others with a history of repetitive…
The Parkinson’s Disease Foundation (PDF) is marking this year’s National Family Caregivers Month by offering a set of free resources to address the unmet needs reported by care partners of Parkinson’s disease patients. PDF is a division of the Parkinson’s Foundation, formed recently by a merger of PDF…
Recent Posts
- New $2M MJFF grant backs Parkinson’s walking study at Boston University
- My fear of falling has gotten worse since my Parkinson’s diagnosis
- New compound targets mitochondrial damage in Parkinson’s models
- Environmental factors may impact Parkinson’s disease risk: Dutch study
- Finding solutions for REM sleep behavior disorder with Parkinson’s